Oct 6 (Reuters) - CombinatoRx Inc said its lead drug candidate to treat knee osteoarthritis failed to meet the main goal of a mid-stage trial, sending its shares crashing 83 percent. The main goal of the trial was to test the efficacy of the drug, Synavive or CRx-102, in reducing pain while walking on a flat surface, compared with a dummy drug.
